Association of death receptor 4 variant (683A>C) with ovarian cancer risk in BRCA1 mutation carriers

International Journal of Cancer

Volumn 130, Issue 6, 2012, Pages 1314-1318

  Dick, Michelle G ^a   Versmold, Beatrix ^a   Engel, Christoph ^b   Meindl, Alfons ^c   Arnold, Norbert ^d   Varon Mateeva, Raymonda ^e   Sutter, Christian ^f   Niederacher, Dieter ^g   Deissler, Helmut ^h   Preisler Adams, Sabine ⁱ   Kast, Karin ^j   Schäfer, Dieter ^k   Gadzicki, Dorothea ^l   Heinritz, Wolfram ^b   Wappenschmidt, Barbara ^a   Schmutzler, Rita K ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g HEINRICH HEINE UNIVERSITY   (Germany)

^h UNIVERSITY OF ULM   (Germany)

ⁱ UNIVERSITY OF MÜNSTER   (Germany)

^j DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^k GOETHE UNIVERSITY   (Germany)

^l HANNOVER MEDICAL SCHOOL   (Germany)

more..

Author keywords

BRCA; breast cancer; death receptor 4; ovarian cancer; SNP

Indexed keywords

ALANINE; CYSTEINE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DEATH RECEPTOR 4 GENE; DNA DETERMINATION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; MUTATOR GENE; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ALLELES; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MUTATION; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; UBIQUITIN-PROTEIN LIGASES;

EID: 84856121432     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26134     Document Type: Article

References (20)

1. Smith CA, Farrah T, Goodwin RG,. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994; 76: 959-62. (Pubitemid 24106376)
2. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM,. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276: 111-3. (Pubitemid 27161256)
3. Fisher MJ, Virmani AK, Wu L, Aplenc R, Harper JC, Powell SM, Rebbeck TR, Sidransky D, Gazdar AF, El-Deiry WS,. Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res 2001; 7: 1688-97. (Pubitemid 32708637)
4. Ashkenazi A, Dixit VM,. Death receptors: signaling and modulation. Science 1998; 281: 1305-8. (Pubitemid 28406815)
5. Hymowitz SG, Christinger HW, Fuh G, Ultsch M, O'Connell M, Kelley RF, Ashkenazi A, de Vos AM,. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell 1999; 4: 563-71. (Pubitemid 29531136)
6. Seitz S, Wassmuth P, Fischer J, Nothnagel A, Jandrig B, Schlag PM, Scherneck S,. Mutation analysis and mRNA expression of trail-receptors in human breast cancer. Int J Cancer 2002; 102: 117-28. (Pubitemid 35168023)
7. Reis CR, van der Sloot AM, Szegezdi E, Natoni A, Tur V, Cool RH, Samali A, Serrano L, Quax WJ,. Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors. Biochemistry 2009; 48: 2180-91.
8. Lee SH, Shin MS, Kim HS, Lee HK, Park WS, Kim SY, Lee JH, Han SY, Park JY, Oh RR, Kang CS, Kim KM, et al. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. Oncogene 2001; 20: 399-403. (Pubitemid 32142330)
9. Emi M, Fujiwara Y, Nakajima T, Tsuchiya E, Tsuda H, Hirohashi S, Maeda Y, Tsuruta K, Miyaki M, Nakamura Y,. Frequent loss of heterozygosity for loci on chromosome 8p in hepatocellular carcinoma, colorectal cancer, and lung cancer. Cancer Res 1992; 52: 5368-72.
10. Kagan J, Stein J, Babaian RJ, Joe YS, Pisters LL, Glassman AB, von Eschenbach AC, Troncoso P,. Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes. Oncogene 1995; 11: 2121-6.
11. Wistuba, II, Behrens C, Virmani AK, Milchgrub S, Syed S, Lam S, Mackay B, Minna JD, Gazdar AF,. Allelic losses at chromosome 8p21-23 are early and frequent events in the pathogenesis of lung cancer. Cancer Res 1999; 59: 1973-9. (Pubitemid 29186174)
12. Yaremko ML, Kutza C, Lyzak J, Mick R, Recant WM, Westbrook CA,. Loss of heterozygosity from the short arm of chromosome 8 is associated with invasive behavior in breast cancer. Genes Chromosomes Cancer 1996; 16: 189-95. (Pubitemid 26231067)
13. Lin DY, WL,. The robust inference for the Cox proportional hazards model. J Am Stat Assoc 1989: 1074-8.
14. Horak P, Pils D, Roessler M, Tomek S, Elandt K, Zeillinger R, Zielinski C, Krainer M,. Common death receptor 4 (DR4) polymorphisms do not predispose to ovarian cancer. Gynecol Oncol 2005; 97: 514-8. (Pubitemid 40614897)
15. Martinez-Ferrandis JI, Rodriguez-Lopez R, Milne RL, Gonzalez E, Cebolla E, Chirivella I, Zamora P, Arias JI, Palacios S, Cervantes A, Diez O, Benitez J, et al. Polymorphisms in TRAIL receptor genes and risk of breast cancer in Spanish women. Cancer Biomark 2007; 3: 89-93. (Pubitemid 47103810)
16. Frank B, Shanmugam KS, Beckmann L, Hemminki K, Brenner H, Hoffmeister M, Chang-Claude J, Burwinkel B,. Death receptor 4 variants and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2006; 15: 2002-5. (Pubitemid 44664282)
17. Hazra A, Chamberlain RM, Grossman HB, Zhu Y, Spitz MR, Wu X,. Death receptor 4 and bladder cancer risk. Cancer Res 2003; 63: 1157-9. (Pubitemid 36348687)
18. Nagane M, Huang HJ, Cavenee WK,. The potential of TRAIL for cancer chemotherapy. Apoptosis 2001; 6: 191-7. (Pubitemid 32423728)
19. Wolf S, Mertens D, Pscherer A, Schroeter P, Winkler D, Grone HJ, Hofele C, Hemminki K, Kumar R, Steineck G, Dohner H, Stilgenbauer S, et al. Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer. Int J Cancer 2006; 118: 1831-5. (Pubitemid 43376450)
20. Frank B, Hemminki K, Shanmugam KS, Meindl A, Klaes R, Schmutzler RK, Wappenschmidt B, Untch M, Bugert P, Bartram CR, Burwinkel B,. Association of death receptor 4 haplotype 626C-683C with an increased breast cancer risk. Carcinogenesis 2005; 26: 1975-7. (Pubitemid 41631272)